Three questions biopharma companies must ask when building a cell and gene commercialization strategy
Breakthroughs in cell and gene therapy (CGT) are accelerating rapidly with more therapies entering the market every year, but the commercialization of these innovations is highly complex. Emerging biopharma companies have to develop a commercialization strategy early in their planning to ensure success at launch and beyond. To that end, biopharma companies must ask themselves the right questions while creating their CGT strategy.
Market access resources
Supply chain and logistics resources
Cold hard facts about cryogenic CGT logistics
World Courier study confirms developers seeking logistical certainty and cold chain integrity from providers with advanced cryogenic capabilities.
Read the white paper to discover how to mitigate risks and build robust logistics platforms that support the clinical development of innovative therapies.
Preserving cell and gene integrity in the supply chain
The development of CGTs is growing at an incredible pace, making it critical to implement processes for frozen and cryogenic storage and distribution. Watch Senior Manager, Personalized Supply Chain, Jennifer Fenwick, explain the pros and cons of fresh and frozen processes and the critical factors to consider.
Packaging solutions product sheets
Clinical to commercialization expertise
Our collection of integrated solutions serve to strategically guide, deliver and support your therapy in market.
Convener within the healthcare ecosystem
Deep connections to providers, payers and patients – no one understand core stakeholders better.
360-degree orchestration and realization
We have proven expertise to securely and compliantly shepherd your therapy through the complex patient journey.
